Table 2.
Univariate associations of nDOR with baseline variables
| HIV-1+ subjects | Control subjects | |||
|---|---|---|---|---|
|
Covariate |
Parameter estimate (95% CI) |
P value |
Parameter estimate (95% CI) |
P value |
| |
Baseline nDOR (normalized ratio). |
|
|
|
|
HDL Cholesterol (ref: ≥35 mg/dl) |
0.357 (0.114, 0.601) |
0.007 |
0.365 (0.029, 0.701) |
0.034 |
|
Body mass index (per 1 kg/m2 increase) |
0.032 (-0.005, 0.069) |
0.086 |
(-) |
(-) |
|
Waist circumference (ref: <90 cm) |
(-) |
(-) |
0.231 (-0.044,0.506) |
0.097 |
|
Waist/Hip ratio (per 0.1 unit increase) |
0.212 (0.035, 0.388) |
0.022 |
0.215 (-0.019, 0.448) |
0.071 |
| |
Yearly rate of change in nDOR (normalized ratio/yr). |
|
|
|
|
Male sex |
0.156 (-0.018, 0.329) |
0.078 |
0.067 (-0.001, 0.144) |
0.085 |
|
White vs Non-White |
0.119 (0.033, 0.206) |
0.008 |
(-) |
(-) |
|
Body mass index (per 1 kg/m2 increase) |
(-) |
(-) |
-0.010 (-0.020, 0.0001) |
0.051 |
|
Reported Nadir CD4 (ref: <200 cells/mm3) |
0.083 (0.039, 0.128) |
<0.001 |
(-) |
(-) |
|
Baseline CIMT (per 1 μm decrease) |
0.474 (0.229, 0.719) |
<0.001 |
(-) |
(-) |
|
HDL Cholesterol (ref: ≥35 mg/dl) |
-0.055 (-0.109, -0.001) |
0.046 |
(-) |
(-) |
|
Insulin (per 10 mU/l decrease) |
(-) |
(-) |
0.120 (0.056, 0.184) |
<0.001 |
| LPS (per 100 pg/ml decrease) | (-) | (-) | 0.005 (0.002, 0.008) | 0.005 |
The baseline variables considered for all subjects were age, gender, race, fasting lipid measurements [total cholesterol, low density lipoprotein (LDL) cholesterol, HDL cholesterol, triglycerides, and non-HDL cholesterol], use of lipid lowering drugs, fasting glucose, body mass index, waist circumference, waist/hip ratio, insulin, high-sensitivity C-reactive protein, homocysteine, sCD14, LPS, and CIMT. For the HIV-1-infected subjects, additional covariates included years of PI use, CD4+ T-cell count, and nadir CD4+ T-cell count.